Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > USA Inflation Reduction Act (IRA) 2022 Re: Biotech and China
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(5289)
•••
Comment by Noteableon Oct 19, 2024 12:22pm
28 Views
Post# 36273107

RE:RE:RE:USA Inflation Reduction Act (IRA) 2022 Re: Biotech and China

RE:RE:RE:USA Inflation Reduction Act (IRA) 2022 Re: Biotech and China

McKinsey Revamps Its China Operations Amid New Risks

Consulting firm cuts hundreds from China workforce, trims state-linked clients and revises strategy for tougher times

By 

Yoko Kubota

 in Beijing and 

Raffaele Huang

 in Singapore

Updated 

 ET
McKinsey has been revising its client list and cutting back on certain projects in China. PHOTO: CHRIS JUNG/ZUMA PRESS

McKinsey is overhauling its China business after cutting back on government-linked clients and reducing the unit’s workforce by nearly 500 people, about a third of the total. 

To reduce security risks associated with doing business in China, the U.S.-based consulting firm has been separating its China operations from other global operations, people familiar with the matter said—a practice increasingly popular among multinational companies.

https://www.wsj.com/business/mckinsey-cuts-hundreds-from-china-workforce-4234e0ad


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities